

## Overview of Obesity and Diabetes landscape in Asia – 2019 update



---

# Contents

<b>1. CLINICAL LANDSCAPE IN ASIA-PACIFIC .....</b>	<b>3</b>
EPIDEMIOLOGY OVERVIEW AND CLINICAL ACTIVITY	3
KEY OPINION LEADERS IN OBESITY AND DIABETES MELLITUS	4
<b>2. NOVOTECH OVERVIEW.....</b>	<b>6</b>
REGISTERED PRODUCT EXPERIENCE	7
NOVOTECH PEOPLE EXPERTISE AND EXPERIENCE	7

# 1. Clinical landscape in Asia-Pacific

## Epidemiology overview and Clinical activity

The prevalence of obesity, and metabolic diseases such as type 2 diabetes has increased significantly in recent years worldwide.

These conditions are endemic in most Western countries, however developing nations across Asia are now seeing a surge in cases due to aging, urbanization, and changing dietary habits. It is estimated that about 80% of the people with diabetes now live in developing countries, and mortality rates due to obesity and diabetes are higher in Asia-Pacific compared to the rest of the world.


A review of the epidemiology of diabetes globally shows developed regions of Asia have an even higher prevalence of the disease than in Europe and North America.

More than 60% of the people with diabetes live in Asia, with almost one-half in China and India combined, while Hong Kong and Singapore have the highest prevalence of diabetes in the world, affecting 12% and 11% of their population respectively.

Biopharma companies initiated about 1,800 trials in diabetes between 2016 and 2018, about half (47%) of which involved a country from the Asia-Pacific. China, Japan, India and South Korea were the most frequently involved countries.

Source: *Diabetes in Asia and the Pacific: Implications for the Global Epidemic. Diabetes Care Mar2016, Vol. 39, p472-485*

Prevalence rate of Type 2 Diabetes (%) in a selection of Western and Asian countries (Source IPD)



Source: GlobalData

---

## Key opinion leaders in obesity and diabetes mellitus

---

### **Prof. RICHARD SIMPSON**

*Eastern Health Endocrinology and Diabetes Centre – AUSTRALIA*

Prof. Simpson is Deputy Director and Founding member of Eastern Health Endocrinology and Diabetes. He established Diabetes and Endocrine services at Box Hill Hospital in Melbourne. He is the co-author of 15 publications including in *Diabetes Care*. Prof Simpson was involved in over 40 clinical studies including 36 trials in obesity and diabetes for Novo Nordisk, AstraZeneca, Diobex, Vervex Pharma, GeNeuro, and BMS.



### **Dr. JOHN WENTWORTH**

*Royal Melbourne Hospital – AUSTRALIA*

Dr. Wentworth is endocrinologist at the Royal Melbourne Hospital and Senior Investigator at Walter and Eliza Hall Institute. He is the co-author of over 30 publications including in *Nature Immunology*. He was involved in 8 clinical studies including 2 late phase trials in obesity and diabetes for King Pharmaceuticals, GSK, Sanofi, Wyeth-Ayerst, and Pfizer.

### **Prof. TANIA MARKOVIC**

*University of Sydney – AUSTRALIA*

Prof. Markovic is Director of the Department of Endocrinology at the Royal Prince Alfred Hospital in Sydney, and is Professor at the Boden Institute of Obesity, Nutrition, Exercise and Eating Disorders at the University of Sydney. She is the co-author of over 25 publications including in *Diabetes Care*. She was involved in 4 clinical studies mostly in late phase trials in obesity and diabetes for AstraZeneca, Eli Lilly, Alkermes, and Zafgen.



### **Prof. HELEN LUNT**

*Christ Church Diabetes Centre – NEW ZEALAND*

Prof. Lunt is Clinical Director at the Health Innovation Hub, Canterbury District Health Board, and a Professor at the University of Otago, Christchurch. She is the co-author of over 30 scientific publications including in *Diabetes Care*. She was involved in 7 clinical studies, mostly on late phase trials in obesity and diabetes for Novo Nordisk, Aradigm, Eli Lilly, Sanofi, MSD, and Lexicon Pharmaceuticals.



**Prof. KIM SOO KYUNG**

*CHA Bundang Medical Centre – SOUTH KOREA*

Prof. Kyung is a Professor at the CHA Bundang Medical Center, and a member of the European Society of Endocrinology. He is the co-author of over 100 publications, including in *Diabetes Care* and was involved in 5 clinical studies in obesity and diabetes mellitus for Novartis, Bayer, Karyopharm Therapeutics, and YiSheng Biopharma.

**Dr. VAISHALI DESHMUKH**

*Deendayal Memorial Hospital – INDIA*

Dr. Deshmukh is Head of the Department of Endocrinology, and Senior Diabetologist at Deenanath Mangeshkar Hospital and Deendayal Memorial Hospital in Pune, India. She is the co-author of 15 publications. She was involved in over 45 clinical studies including 4 late phase trials in obesity and diabetes for Biocon, MJ Biopharm, Novo Nordisk, Boehringer Ingelheim, and Eli Lilly.



**Dr. WING SUN CHOW**

*The University of Hong Kong – HONG KONG*

Dr. Sun Chow is a Professor at the University of Hong Kong and Secretary of the Hong Kong Society of Endocrinology. He is the co-author of over 30 publications and he was involved in 7 clinical studies including 3 late phase trials in obesity and diabetes mellitus for Bayer, MSD, and GSK.

**Prof. FRANCIS CC CHOW**

*Chinese University of Hong Kong – HONG KONG*

Prof. Chow is Associate Professor at the Hong Kong Institute of Diabetes and Obesity. He currently serves as Consultant and Chief of Service of the Department of Medicine and Therapeutics at the Prince of Wales Hospital. He is the co-author of over 40 publications including in *Diabetes Care* and was involved in over 30 clinical studies including 24 early and late phase trials in obesity and diabetes Mellitus for Novo Nordisk, Novartis, Merck, Ajinomoto, Kyorin Pharma, and Frosst Canada.



## 2. Novotech Overview

Novotech is internationally recognized as the leading regional full-service contract research organization (CRO) in the Asia Pacific region. Novotech provides clinical development services across all therapeutic areas and has been instrumental in the success of hundreds of Phase I - IV clinical trials.



**Full service CRO with on-the-ground operations** in Australia, New Zealand, India, South Korea, Taiwan, Thailand, Malaysia and Singapore, the Philippines, Hong Kong and China.

**600+ full-time employees**

**Best in class technology solutions** including CTMS (Oracle Siebel), eDC (Medidata Rave, Oracle Inform), eTMF (SureClinical) and Safety (Oracle Argus)

**Extensive therapeutic area experience handling clinical studies with biopharma companies** across all phases of clinical trials

**Managed APAC component of pivotal trials** for multiple FDA, EMA registered products since 2001

**Established in 1996**, with head office in Sydney, Australia

Recipient of the 2019 Frost & Sullivan **Asia Pacific Biotech CRO Company of the Year** award for the 4<sup>th</sup> consecutive year.

### Full service CRO



### Services

## Registered product experience

Novotech has successfully managed the APAC component of over 20 FDA and EMA registered compounds and devices. This speaks to the quality of the data generated from Novotech sites across the region and to our experience working on large pivotal studies for US and EU based biotech.

Abraxane (breast, lung, and pancreatic cancer)	Nerlynx (HER2-positive breast cancer)
Cellegesic (hemorrhoids)	Nothera (orthostatic hypertension)
Depodur (post-operative pain)	Ocaliva (primary biliary cirrhosis)
Firazyr (hereditary angioedema)	Solaraze (actinic and solar keratosis)
Galafold (Fabry's disease)	Tarceva (NSCLC and pancreatic cancer)
GC Flu H5N1 Multi Injection (influenza)	Vimpat (partial-onset seizures)
Hismanal (allergic rhinitis)	Xiaflex (Dupuytren's and Peyronie's contracture)
Istodax (T-cell lymphomas)	Xtandi (prostate cancer)
Levact (chronic lymphocytic leukemia)	Zilretta (osteoarthritic knee pain)
Lucentis (wet AMD)	Zurampic (gout)
Metvix PDT (skin cancer)	Zytiga (prostate cancer)

## Novotech people expertise and experience

Novotech has many of the most experienced professionals in the industry.

### Average years of Novotech staff experience

